Merck and 4SC collaborate in immunooncology4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat. more ➔
Novo Holdings invest US$12m in AMR companiesMutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund. more ➔
Fighting sepsis mortality Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality. more ➔
Antabio SAS advances cystic fibrosis programme Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients more ➔
Hydrogel fights wound infection and inflammation Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds. more ➔
British diagnostics play OBD lands contract with US pharmaThe technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic … more ➔
Truffle’s BioMedTech fund filled with €250mParis-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach. more ➔
Cellestia: €20m to get to Phase IIBasel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million. more ➔
Biomarker identifies residual congestion in heart failure patientsData from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients. more ➔
Belgian start-up takes fight on neuropathiesThe new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with €4.2m from mainly local investors, … more ➔
